BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24290218)

  • 1. Novel treatment options for Waldenström macroglobulinemia.
    Leblebjian H; Agarwal A; Ghobrial I
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S310-6. PubMed ID: 24290218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome Inhibitors in Waldenström Macroglobulinemia.
    Kastritis E; Dimopoulos MA
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):829-840. PubMed ID: 30190021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the bone marrow in Waldenstrom macroglobulinemia.
    Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa GC; Leleu X; Roccaro AM
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S65-9. PubMed ID: 22035751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is new in the treatment of Waldenstrom macroglobulinemia?
    Castillo JJ; Treon SP
    Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waldenstrom macroglobulinemia.
    Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
    Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
    Yun S; Johnson AC; Okolo ON; Arnold SJ; McBride A; Zhang L; Baz RC; Anwer F
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):252-262. PubMed ID: 28366781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
    Jalali S; Ansell SM
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment options for Waldenström macroglobulinemia.
    Vijay A; Gertz MA
    Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bone marrow microenvironment in Waldenström macroglobulinemia.
    Agarwal A; Ghobrial IM
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):218-21. PubMed ID: 23490994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waldenström macroglobulinemia: from biology to treatment.
    Sahin I; Leblebjian H; Treon SP; Ghobrial IM
    Expert Rev Hematol; 2014 Feb; 7(1):157-68. PubMed ID: 24405328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in Waldenström macroglobulinemia.
    Burwick N; Roccaro AM; Leleu X; Ghobrial IM
    Curr Opin Investig Drugs; 2008 Jun; 9(6):631-7. PubMed ID: 18516762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
    Castillo JJ; Ghobrial IM; Treon SP
    Cancer Treat Res; 2015; 165():177-95. PubMed ID: 25655610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waldenström macroglobulinemia.
    Treon SP; Hunter ZR; Castillo JJ; Merlini G
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waldenström macroglobulinemia.
    Kasi PM; Ansell SM; Gertz MA
    Clin Adv Hematol Oncol; 2015 Jan; 13(1):56-66. PubMed ID: 25679974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on therapeutic options in Waldenström macroglobulinemia.
    Leleu X; Gay J; Roccaro AM; Moreau AS; Poulain S; Dulery R; Champs BB; Robu D; Ghobrial IM
    Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
    Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
    Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents in Waldenström macroglobulinemia.
    Issa GC; Ghobrial IM; Roccaro AM
    Clin Investig (Lond); 2011; 1(6):815-824. PubMed ID: 22034589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waldenström macroglobulinemia: What a hematologist needs to know.
    Kapoor P; Paludo J; Vallumsetla N; Greipp PR
    Blood Rev; 2015 Sep; 29(5):301-19. PubMed ID: 25882617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.